Two early stage biotechnology companies in the Conejo Valley announced the launch of clinical studies for their dermatology products in February. Thousand Oaks-based Dyve Biosciences said Feb. 20 it had enrolled its first patient in a Phase 2 study of its topical gout therapy DYV-700. The news came shortly after the Central Coast’s newest public…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
